Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2011-08-30
2011-08-30
Navarro, Albert (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S193100, C424S234100, C424S278100
Reexamination Certificate
active
08007806
ABSTRACT:
The present invention relates to a composition comprising at least one fibronectin binding protein, and/or at least one a truncated fibronectin binding protein and/or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one Iscom matrix complex and/or liposome and/or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the production of a vaccine against a micro organism that comprises at least one one fibronectin binding domain. It also regards a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and/or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and/or an Iscom matrix complex and/or an iscom complex and or a liposome. Further it relates to a method for vaccination of an individual.
REFERENCES:
patent: 4900549 (1990-02-01), De Vries et al.
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5270168 (1993-12-01), Grinnell
patent: 5540933 (1996-07-01), Ruoslahti et al.
patent: 5618916 (1997-04-01), Ratliff et al.
patent: 5620690 (1997-04-01), Kersten et al.
patent: 5679354 (1997-10-01), Morein et al.
patent: 5753235 (1998-05-01), Haanes et al.
patent: 5925359 (1999-07-01), Van Woensel et al.
patent: 6177081 (2001-01-01), Wechter et al.
patent: 6231859 (2001-05-01), Kensil
patent: 6288214 (2001-09-01), Hook et al.
patent: 6352697 (2002-03-01), Cox et al.
patent: 6428807 (2002-08-01), MacFarlan et al.
patent: 6558670 (2003-05-01), Friede et al.
patent: 7838019 (2010-11-01), Morein et al.
patent: 2006/0121065 (2006-06-01), Morein et al.
patent: 2006/0239963 (2006-10-01), Morein et al.
patent: 0 109 942 (1984-05-01), None
patent: 0440289 (1991-08-01), None
patent: 0 362 279 (1995-01-01), None
patent: 88/09336 (1988-12-01), None
patent: 90/03184 (1990-04-01), None
patent: WO-9103572 (1991-03-01), None
patent: 96/11711 (1996-04-01), None
patent: 97/30728 (1997-08-01), None
patent: 98/36772 (1998-08-01), None
patent: 2004/004762 (2004-01-01), None
patent: WO-2004004762 (2004-01-01), None
patent: 2004/030696 (2004-04-01), None
patent: 2005002620 (2005-01-01), None
patent: WO-2005002620 (2005-01-01), None
“European Application Serial No. 06701328.4, Communication mailed Jan. 22, 2010”, 4 pgs.
Pearse, M. J., et al., “ISCOMATRIX® adjuvant for antigen delivery”,Advanced Drug Delivery Reviews, 57, (2005), 465-474.
“European Application Serial No. 06701328.4, Communication and Supplementary European Search Report mailed Oct. 9, 2008”, 7 pgs.
Brennan, Frank R., et al., “Chimeric Plant Virus Particles Administered Nasally or Orally Induce Systemic and Mucosal Immune Responses in Mice”,Journal of Virology, vol. 73, No. 2, (Feb. 1999), 930-938.
McArthur, J., et al., “Immune responses of a liposome/ISCOM vaccine adjuvant against streptococcal fibronectin binding protein 1 (Sfb1) in mice”,Indian J Med Res 119, (Suppl), (May 2004), 115-120.
Nelson, L., et al., “Adhesins inStaphylococcal mastitisas Vaccine Components”,Flemish Veterinary Journal, vol. 62, Suppl. 1, Chapter 8, (1991), 111-125.
“Chinese Application Serial No. 20060002650.3, Second Office Action dated Feb. 5, 2010”, (English Translation), 16 pgs.
“Safety Evaluation of Certain Food Additives and Contaminants Quillaja Extracts, ”WHO food Additives Series: 48, 2002.
Morein, B. et al.; Iscom, A Novel Structure for Antigenic Presentation of Membrane Proteins from Enveloped Viruses; Nature, vol. 308, No. 5958, Mar. 29, 1984; pp. 457-460; Macmillan Journals Ltd., 1984.
Pierre Tiollais, Christine Pourcel & Anne Dejean, “The Hepatitis B Virus”, Oct. 10, 1985, Nature, vol. 317, pp. 489-495.
Chavali S., et al., Adjuvant Effects of Orally Administered Saponins on Humoral and Cellular Immune Responses in Mice; Immunobiol., vol. 174, Mar. 2, 1987, pp. 347-359.
Chavali S., et al., An Invitro Study of Immunomodulatory Effects of Some Saponins; International Society for Immunopharmacology, vol. 9, No. 6, Mar. 24, 1987, Great Britain, pp. 675-683.
Pyle, S.W., Morein, B., Bess, J.W., Akerblom, L., Nara, P.L., Nigida, S.M., Lerche, N.W., Robey, W.G., Fischinger, P. J., and Arthur, L.O., “Immune Response to Immunostimulatory Complexes (ISCOMS) Prepared from Human Immunodeficiency Virus Type 1 (HIV-1) or the HIV-1 External Envelope Glycoprotein (gp120),” Vaccine, vol. 7, 1989, 465-473.
Takahashi, Hidemi et al., Inductin of CD8 Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs; Nature, vol. 344, Apr. 26, 1990; pp. 873-875.
Fohlman, Jan et al., Vaccination of Balb/c mice against enteroviral mediated myocarditis; Vaccine, vol. 8, Aug. 1990; Butterworth-Heineman Ltd; pp. 381-384.
P.G.W. Plagemann, “Hepatitis C Virus”, Jun. 4, 1991, Arch Virol, vol. 120, pp. 165-180.
Gupta et al., “Adjuvants-a balance between toxicity and adjuvanticity,” Vaccine, vol. 11 No. 3, pp. 293-306 (1993).
Lipford et al., “Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytoxtoxic T cells,” Vaccine, vol. 12 No. 1, pp. 73-80 (Jan. 1994).
Sjolander, A. Bengtsson, K.L., Johansson, M. and Morein, B., “Kinetics, Localization and Isotype Profile of Antibody Responses to Immune Stimulating Complexes (ISCOMS) Containing Human Influenza Virus Envelope Glycoproteins,” Scand. J. Immunol. 43, 1996, 164-172.
Barr, Ian G., et al., ISCOMs (immunostimulating complexes): The first decade; CSL Limited, Parkville, Victoria, Australia; Immunology and Cell Biology (1996) vol. 74, pp. 8-15.
“Committee for Veterinary Medicinal Products, Quillaia Saponins, Summary Report”, The European Agency for the Evaluation of Medicinal Products, EMEA/MRL/055/95-final, Feb. 1996, pp. 1-2.
SIGMA Product Information; techserv@sial.com; Saponin From Quillaja Bark Purified; Sigma Prod. No. S4521; Case No. 8047-15-2; Oct. 25, 1996; pp. 1-3.
Sjolander, A., Bengtsson, K.L., and Morein, B., “Kinetics, Localization and Cytokine Profile of T Cell Responses to Immune Stimulating Complexes (ISCOMS) Containing Human Influenza Virus Envelope Glycoproteins,” Vaccine, vol. 15, No. 9, 1997, 1030-1038.
Sjolander, A., Land, B.V., and Bengtsson, K.L., “ISCOMS Containing Purified Quillaja Saponins Upregulate both Th1-like and Th2-like Immune Responses,” Cellular Immunology, 177, 1997, 69-76.
van Binnendijk et al, 1997. Protective immunity in Macaques vaccinated with live attenuated recombinant and subunit vaccines in the presence of passively acquired antibodies. “J. Infect Diseases” vol. 175, pp. 524-532.
Yifan Zhan et al., 1998, “Control of IL-12 and IFN-y Production in Response to Live or Dead Bacteria by TNF and Other Factors,” The Journal of Immunology, 161, pp. 1447-1453.
Smith, R.E., Donachie, A.M., and Mcl Mowat, A., “Immune Stimulating Complexes as Mucosal Vaccines,” Immunology and Cell Biology, 76, 1998, 263-269.
Karen Burke, Glynis Dunn, Morag Ferguson, Philip D. Minor, & Jeffrey W. Alamond, “Antigen Chimaeras of Poliovirus as Potential New Vaccines”, Nature, vol. 332. Mar. 1988. (Abstract Only).
The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit; Committee for Proprietary Medicinal products, Note for Guidance on Pharmaceutical and Biological Aspects of Combined Vaccines; London, Jul. 23, 1998 pp. 1-14.
Rosemary E. Smith et al, 1999, “Immune-Stimulating Complexes Induce an IL-12Dependent Cascade of Innate Immune Responses,” The Journal of Immunology, 162, pp. 5536-5546.
Margaretha Johansson et al. “ISCOMS with Different Quillaja Saponin Components Differ in Their Immunomodulating Activities.ȁ
Baschunan Carlos Concha
Ekstrom Jill
Fromgren Birgitta
Lövgren-Bengtsson Karin
Morein Bror
Isconova AB
Navarro Albert
Pearne & Gordon LLP
LandOfFree
Vaccine composition comprising a fibronectin binding protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine composition comprising a fibronectin binding protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine composition comprising a fibronectin binding protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649670